• Sebastián Cabrera, Magdalena Walbaum, Eduardo Lorca, Tamara Bórquez, Sergio Mezzano, Rodrigo Tagle, Eric Zuñiga, Pamela Belmar, Gonzalo Godoy, Marcelo Vargas, Gina Brun, Jorge Donat, Camilo Cortés, and Luis Sepúlveda.
• Sociedad Chilena de Nefrología, Santiago, Chile.
• Rev Med Chil. 2024 Feb 1; 152 (2): 244252244-252.

AbstractThe Chilean consensus on the use of SGLT-2 inhibitors (iSGLT-2) in clinical practice, jointly developed by the societies of Cardiology, Diabetes, Family Medicine, and Nephrology, strongly recommends the use of these drugs in people with heart failure with reduced ejection fraction, type 2 diabetes mellitus for prevention of cardiovascular events, and chronic kidney disease. In heart failure with preserved or mildly reduced ejection fraction, and chronic kidney disease without diabetes, the consensus suggests the use of iSGLT-2. The importance of combining iSGLT-2 with ACE inhibitors or ARBs in chronic kidney disease is highlighted, and their use is recommended to replace sulfonylureas as a second-line treatment for glycemic control in type 2 diabetes. The consensus emphasizes the need for strategies to optimize diagnosis, improve adherence, and educate about benefits beyond glycemic control. Safety and cost-effectiveness considerations for prioritized implementation according to evidence are discussed. The document highlights the importance of multidisciplinary collaboration and the generation of local evidence to maximize the potential of these drugs in the management of complex cardiometabolic conditions in Chile.

18 keywords...

hide…